Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 610 participants.
Also called NCT04020263
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 610 participants
- Sponsor
- Pr Bruno LEVY
- Registry
-
NCT04020263 -
2024-513811-29-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- France
- Registry status
- Recruiting
Technical summary
Registry record NCT04020263. Randomized; triple masking; primary purpose treatment. Start 2023-07-03 (actual); primary completion 2027-02-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock
- Acronym
- LevoHeartShock
- Condition
- Cardiogenic Shock
- Intervention (Drug)
- Levosimendan 2.5 MG/ML Injectable Solution
- Intervention (Drug)
- Placebo
- Lead sponsor
- Pr Bruno LEVY
Record details
- Record id
cardio:ct-nct04020263- Content hash
616324abb24b2538721236185ca1fa691f1467a16096c0b8c3070056d24a9c5b